Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Angelo Brunelli Albertoni Laranjeira"'
Autor:
Nathália Moreno Cury, Tobias Mühlethaler, Angelo Brunelli Albertoni Laranjeira, Rafael Renatino Canevarolo, Priscila Pini Zenatti, Daniel Lucena-Agell, Isabel Barasoain, Chunhua Song, Dongxiao Sun, Sinisa Dovat, Rosendo Augusto Yunes, Andrea Enrico Prota, Michel Olivier Steinmetz, José Fernando Díaz, José Andrés Yunes
Publikováno v:
iScience, Vol 21, Iss , Pp 95-109 (2019)
Summary: Tubulin is one of the best validated anti-cancer targets, but most anti-tubulin agents have unfavorable therapeutic indexes. Here, we characterized the tubulin-binding activity, the mechanism of action, and the in vivo anti-leukemia efficacy
Externí odkaz:
https://doaj.org/article/67ad75df1ed143b6b2d81f30461805ab
Autor:
Mateus Milani, Angelo Brunelli Albertoni Laranjeira, Jaíra Ferreira de Vasconcellos, Silvia Regina Brandalise, Alexandre Eduardo Nowill, José Andrés Yunes
Publikováno v:
PLoS ONE, Vol 10, Iss 6, p e0129298 (2015)
Current monitoring of acute lymphoblastic leukemia (ALL) in living mice is based on FACS analysis of blood hCD45+ cells. In this work, we evaluated the use of human IGFBP2, B2M or Hsp90 as soluble markers of leukemia. ELISA for B2M and IGFBP2 resulte
Externí odkaz:
https://doaj.org/article/d82610bebac34cfa9320d79c069cd9e4
Autor:
Mateus Milani, Angelo Brunelli Albertoni Laranjeira, Jaíra Ferreira de Vasconcellos, Silvia Regina Brandalise, Alexandre Eduardo Nowill, José Andrés Yunes
Publikováno v:
PLoS ONE, Vol 10, Iss 7, p e0134774 (2015)
[This corrects the article DOI: 10.1371/journal.pone.0129298.].
Externí odkaz:
https://doaj.org/article/36dbbee8ad8349828a8bc0fca1b6fc2b
Autor:
Raoni Pais Siqueira, Éverton de Almeida Alves Barbosa, Marcelo Depólo Polêto, Germanna Lima Righetto, Thiago Vargas Seraphim, Rafael Locatelli Salgado, Joana Gasperazzo Ferreira, Marcus Vinícius de Andrade Barros, Leandro Licursi de Oliveira, Angelo Brunelli Albertoni Laranjeira, Márcia Rogéria Almeida, Abelardo Silva Júnior, Juliana Lopes Rangel Fietto, Jörg Kobarg, Eduardo Basílio de Oliveira, Robson Ricardo Teixeira, Júlio César Borges, Jose Andrés Yunes, Gustavo Costa Bressan
Publikováno v:
PLoS ONE, Vol 10, Iss 8, p e0134882 (2015)
Dysregulation of pre-mRNA splicing machinery activity has been related to the biogenesis of several diseases. The serine/arginine-rich protein kinase family (SRPKs) plays a critical role in regulating pre-mRNA splicing events through the extensive ph
Externí odkaz:
https://doaj.org/article/601ab0b89b354a30a64f7d7fa31722bb
Autor:
Jaíra Ferreira de Vasconcellos, Angelo Brunelli Albertoni Laranjeira, Paulo C Leal, Manoj K Bhasin, Priscila Pini Zenatti, Ricardo J Nunes, Rosendo A Yunes, Alexandre E Nowill, Towia A Libermann, Luiz Fernando Zerbini, José Andrés Yunes
Publikováno v:
PLoS ONE, Vol 10, Iss 8, p e0134783 (2015)
Acute Lymphoblastic Leukemia (ALL) is the most frequent childhood malignancy. In the effort to find new anti-leukemic agents, we evaluated the small drug SB225002 (N-(2-hydroxy-4-nitrophenyl)-N'-(2-bromophenyl)urea). Although initially described as a
Externí odkaz:
https://doaj.org/article/e9843bd459894264bbf568c153565b4f
Autor:
Daniel Antunes Moreno, Howard Lopes Ribeiro Junior, Angelo Brunelli Albertoni Laranjeira, Gustavo Alencastro Veiga Cruzeiro, Kleiton Silva Borges, Karina Bezerra Salomão, Fernando Silva Ramalho, José Andres Yunes, Cleide Lúcia Araújo Silva, Eduardo Magalhães Rego, Carlos Alberto Scrideli, Luiz Gonzaga Tone
Patients diagnosed with acute lymphoblastic leukemia (ALL) bearing t(4;11)/MLL-AF4 have aggressive clinical features, poor prognosis and there’s an urgent need for new therapies to improve outcomes. Panobinostat (LBH589) has been identified as a po
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f7eead5c4f8e0f6ca7f120150d783221
https://doi.org/10.21203/rs.3.rs-1594461/v1
https://doi.org/10.21203/rs.3.rs-1594461/v1
Autor:
Daniel Antunes Moreno, Howard Lopes Ribeiro Junior, Angelo Brunelli Albertoni Laranjeira, Gustavo Alencastro Veiga Cruzeiro, Kleiton Silva Borges, Karina Bezerra Salomão, Fernando Silva Ramalho, José Andres Yunes, Cleide Lúcia Araújo Silva, Eduardo Magalhães Rego, Carlos Alberto Scrideli, Luiz Gonzaga Tone
Publikováno v:
Medical oncology (Northwood, London, England). 39(12)
Patients diagnosed with acute lymphoblastic leukemia (ALL) bearing t(4;11)/MLL-AF4 have aggressive clinical features, poor prognosis and there is an urgent need for new therapies to improve outcomes. Panobinostat (LBH589) has been identified as a pot
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc59f21322e631026d0453b56858e2e2
https://pubmed.ncbi.nlm.nih.gov/36175721
https://pubmed.ncbi.nlm.nih.gov/36175721
Autor:
Elisa De Togni, Mary C. Fulbright, Grant A. Challen, Hamza Celik, Marianna B. Ruzinova, Stephen T. Oh, Abigail J Wong, Angelo Brunelli Albertoni Laranjeira, Daniel A.C. Fisher, Tim Kong, Taylor B. Collins
Publikováno v:
Blood Advances
Key Points Pevonedistat targets the NFκB pathway to inhibit growth of MPN and sAML cells.Pevonedistat reduces disease burden in MPN mouse models.
Visual Abstract
Targeted inhibitors of JAK2 (eg ruxolitinib) often provide symptomatic relief
Visual Abstract
Targeted inhibitors of JAK2 (eg ruxolitinib) often provide symptomatic relief
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff881d98aa77152af9d1c0e8e80251a5
https://pubmed.ncbi.nlm.nih.gov/34644371
https://pubmed.ncbi.nlm.nih.gov/34644371
Autor:
Pedro O. de Campos-Lima, José Andrés Yunes, Silvia Regina Brandalise, Rosemary Assis, Angelo Brunelli Albertoni Laranjeira
Publikováno v:
Experimental Hematology & Oncology, Vol 6, Iss 1, Pp 1-11 (2017)
Experimental Hematology & Oncology
Experimental Hematology & Oncology
Background Inflammation is a major feature of sickle cell disease (SCD). Low-dose methotrexate (MTX) has long been used in chronic inflammatory diseases. This pilot study examined the MTX effect on acute vaso-occlusive pain crises (VOC) in SCD patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::88e76a8dfd9a57d71752725325d173ae
http://link.springer.com/article/10.1186/s40164-017-0078-1
http://link.springer.com/article/10.1186/s40164-017-0078-1
Autor:
Isabel Barasoain, Nathalia Moreno Cury, José Andrés Yunes, Andrea E. Prota, Dongxiao Sun, Chunhua Song, Priscila Pini Zenatti, Tobias Mühlethaler, Sinisa Dovat, Angelo Brunelli Albertoni Laranjeira, Daniel Lucena-Agell, Rosendo A. Yunes, Michel O. Steinmetz, Rafael Renatino Canevarolo, José Fernando Díaz
Publikováno v:
iScience
iScience, Vol 21, Iss, Pp 95-109 (2019)
Digital.CSIC. Repositorio Institucional del CSIC
instname
iScience, Vol 21, Iss, Pp 95-109 (2019)
Digital.CSIC. Repositorio Institucional del CSIC
instname
Summary Tubulin is one of the best validated anti-cancer targets, but most anti-tubulin agents have unfavorable therapeutic indexes. Here, we characterized the tubulin-binding activity, the mechanism of action, and the in vivo anti-leukemia efficacy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c0bb83c0d7ffcebf6ee1c2439a6bd23
https://pubmed.ncbi.nlm.nih.gov/31655259
https://pubmed.ncbi.nlm.nih.gov/31655259